ASC-CM Therapy for ARDS Lung Inflammation and Barrier Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Adult Respiratory Distress Syndrome (ARDS) are largely supportive and fail to improve mortality, as they target separate components of pathogenesis without addressing the need for lung repair and inflammation reduction.
Innovation Solution
Administration of Adult Stem Cell Conditioned Media (ASC-CM), which is derived from cultured Adult Stem Cells (ASCs), to intravenously treat patients with ARDS, reducing inflammation, lung histopathologic changes, and mortality associated with ARDS and respiratory infections like MERS/SARS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supportive treatments (oxygenation, fluid control) are used for ARDS, then patient survival is maintained, but mortality remains high and lung repair is not facilitated
Solution Approach 1:
ASC-CM acts as an intermediary substance that mediates between the harmful inflammatory response and the lung tissue. It contains bioactive molecules (growth factors, cytokines, exosomes) that directly interact with inflamed lung parenchyma to reduce inflammation and promote repair, bridging the gap between supportive care and active treatment.
Solution Approach 2:
The invention changes the therapeutic parameter from passive supportive care to active biological intervention. ASC-CM introduces new active components (stem cell-derived factors) that fundamentally alter the disease course by modulating inflammation and promoting regeneration, rather than merely maintaining physiological parameters.
2Object-affected harmful factors
If pharmacological strategies targeting separate pathogenesis components are used, then specific mechanisms are addressed, but overall mortality is not improved
Solution Approach 1:
ASC-CM provides multi-functional therapy by simultaneously addressing multiple pathogenesis mechanisms. It exhibits anti-inflammatory activity, pro-angiogenic activity, and tissue repair promotion in a single therapeutic agent, eliminating the need for multiple separate pharmacological interventions.
Solution Approach 2:
ASC-CM is a composite biological material containing diverse bioactive molecules including growth factors (VEGF, FGF, EGF), cytokines, chemokines, and exosomes. This composite composition allows it to target multiple pathological processes simultaneously, providing synergistic therapeutic effects that single agents cannot achieve.
3Object-affected harmful factors
If ASC-CM is administered to treat ARDS, then inflammation and lung histopathologic changes are reduced, but treatment complexity increases
Solution Approach 1:
The invention extracts the therapeutic essence of adult stem cells by culturing them and collecting their conditioned media. This separates the beneficial bioactive molecules from the complex living cell system, creating a stable, controllable, and scalable treatment that avoids the complexities of live cell transplantation while retaining therapeutic efficacy.
Data Source
AI summary
Disclosed herein is that the systemic administration of ASC conditioned media diminished LPS-induced lung injury by inhibiting epithelial permeability, neutrophil inflammatory response, and secretion of pro-inflammatory TNFα. It is also shown that ARDS lung is able to retain IV-delivered ASC for a substantial amount of time, with no evidence of the significant cell distribution to other organs at this time point. These findings provide optimization of cell-based and cell-free therapy for the treatment of ARDS, including occurrences of ARDS caused by upper respiratory tract infections such as SARS and MERS.